Articles On Compumedics (ASX:CMP)

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The company continues to actively pursue step-out commercial growth opportunities for the MEG and Somfit technology platforms.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Summary Logistic problems have impacted the revenue pipeline of the company. Compumedics continues to pursue potential sales opportunities in the US market. Compumedics Limited (ASX:CMP) released a business update on Wednesday. The...

Last week in our discussion with Bourse Communication founder and Managing Director Rod North, we examined how COVID-19 compared to other great market impacting events such as the 1987 crash the recession we had to have. This week, we look...

In just two years, skin regenerator Avita Medical (ASX:AVH) has shot up from 6c to 40c and was granted entry into the ASX 200, but the company says it hasn’t made it yet. Chief financial officer David McIntyre, who joined Avita in November...

The Compumedics Limited (ASX: CMP) share price will be one to watch this morning following the release of the medical device company’s half year results. How did Compumedics perform in the first half? During the six months ended December 3...

At time of writing, the share price of Compumedics Ltd [ASX:CMP] is up a significant 25.47% on important FDA approval. It’s been a remarkable 12 months for the stock, with the Compumedics share price rising a total of 154% during this perio...

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

Compumedics (ASX: CMP) has collared US Food and Drug Administration approval for its neuroimaging technology, enabling insurers to be billed for the scan. On Friday, the FDA officially granted 510(K) clearance to Compumedics for its Orion L...

The Compumedics Limited (ASX: CMP) share price has started the week with a bang. In morning trade the medical device company’s shares rocketed a massive 26% higher to 87.5 cents. Why is the Compumedics share price rocketing higher today? I...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

In afternoon trade the S&P/ASX 200 index is on course to start the week on a disappointing note. At the time of writing the benchmark index is down 0.45% to 6,896.8 1 points. Four shares that are falling more than most today are listed...

No one likes to hear of a revenue downgrade and shareholders of sleep and brain disorder medical device manufacturer Compumedics (ASX:CMP) are no different. While the company’s earnings guidance for the full year was still $6.5m-$7.5m, unau...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The Compumedics Limited (ASX: CMP) share price is crashing lower on Monday. At the time of writing the medical device company’s shares are down 22% to 61 cents. Why is the Compumedics shares price sinking lower? Investors have been selling...

In 2019 the culmination of decades worth of work turned several biotechs and life sciences companies into overnight successes. As investors look to defensive growth stocks to compensate for a sluggish economy and with expectations of more h...